Preventive Vaccines - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The preventive vaccines market size is estimated at USD 79.52 billion in 2026, and is expected to reach USD 103.73 billion by 2031, at a CAGR of 5.46% during the forecast period (2026-2031). This report is Segmented by Vaccine Type (Live/Attenuated Vaccines, Inactivated Vaccines and More), Disease Type (Pneumococcal, Poliovirus, Hepatitis, Influenza, Measles, Mumps, and Rubella (MMR), and More), Age Group (Pediatrics, Adolescents, and More), End-User (Government Immunization Programs, and More), and Geography (North America, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Preventive Vaccines Market Trends and Insights

Growing Prevalence of Infectious Diseases

Measles cases climbed 15% across Southeast Asia and Sub-Saharan Africa from 2024 to 2025, reversing a decade of gains and triggering 60-day emergency procurements that reward suppliers with modular fill-finish lines. Vector expansion linked to urbanization and climate change is pushing clinicians to prioritize prevention for pathogens such as pneumococcus. U.S. RSV hospitalizations among infants rose 22% in the 2024-2025 season, prompting a maternal vaccination recommendation that opens an additional 3.7 million annual births to immunization. The net effect is a surge in base demand that reinforces the preventive vaccines market as a long-term growth platform.

Government Immunization Funding & Mandates

Global public budgets for vaccination escalated to USD 18.3 billion in 2025, up from USD 14.1 billion in 2023, as policymakers internalize outbreak costs. The U.S. Vaccines for Children program widened eligibility to uninsured adults aged 19-26, adding 4.2 million beneficiaries for HPV and meningococcal coverage. India’s nationwide pneumococcal tender worth USD 420 million split evenly between Serum Institute and Bharat Biotech, underscoring domestic supply preference. Tightening school and workplace mandates in Europe are closing exemption loopholes and shoring up baseline uptake.

Risk of Adverse Events & Hesitancy Spikes

The European Medicines Agency logged 1,847 serious events per 100 million doses in 2025, a flat rate versus 2023, yet social amplification temporarily depressed uptake. A well-publicized myocarditis case cut U.S. confidence by 9 points but rebounded within 8 months after updated risk-benefit data showed only 12.6 myocarditis cases per million doses against 450 hospitalizations averted per million COVID-19 infections. WHO’s Vaccine Safety Net flagged 3,200 misinformation posts reaching 50 million users, necessitating real-time fact-checking deals with platforms.

Other drivers and restraints analyzed in the detailed report include:

• Breakthroughs in mRNA & Modular Vaccine Platforms
• Expansion of Life-Course (Adult & Senior) Vaccination Programs
• High R&D and Compliance Costs

Segment Analysis

Live and attenuated products retained 26.55% preventive vaccines market share in 2025, anchored by MMR and varicella schedules. Subunit and recombinant platforms are forecast to advance at a 6.25% CAGR as regulators favor constructs that remove reversion risk and simplify logistics. Pfizer’s 20-valent Prevnar 20 secured 38% of the U.S. adult market within 12 months of its June 2024 launch by expanding serotype coverage. Inactivated polio and hepatitis A vaccines continue to dominate mass campaigns where dose cost rules procurement. Toxoid options retain steady booster demand tied to obstetric care and injury prophylaxis.

Momentum for mRNA vaccines extends beyond COVID-19 into influenza and RSV indications. Moderna began Phase III testing of a combined mRNA flu-COVID shot in January 2025, eyeing a 2027 launch that consolidates two annual injections into one. BioNTech’s malaria candidate entered Phase IIb in Tanzania and Mozambique during 2025, reusing its lipid nanoparticle platform to shave 3-4 years off typical timelines. Viral-vector and virus-like particle constructs play niche roles such as Ebola rings and HPV campaigns in cost-sensitive markets.

Influenza held 20.53% of disease revenue in 2025, sustained by annual reformulation and employer programs. Measles-mumps-rubella vaccines are projected to grow 6.85% CAGR through 2031 as pandemic-era coverage gaps spark outbreaks; WHO tallied 120,000 measles cases in 2024, a 40% jump year over year. Pneumococcal vaccines benefit from wider age indications addressing resistant strains circulating in hospitals.

COVID-19 boosters transitioned to endemic status in 2025 with annual recommendations for older adults, generating USD 6.2 billion revenue in Q4 2025 alone for Pfizer and Moderna. HPV uptake accelerates in LMICs thanks to single-dose Gavi guidelines that cut costs 60% while maintaining efficacy. RSV shots for older adults and maternal schedules constitute the fastest-growing slice, a category absent before mid-2023.

Complete Report Scope:

• By Vaccine Type
  • Live / Attenuated Vaccines
  • Inactivated Vaccines
  • Subunit / Recombinant Vaccines
  • Toxoid Vaccines
  • mRNA Vaccines
  • Other Vaccine Types
• By Disease Type
  • Pneumococcal
  • Poliovirus
  • Hepatitis (A, B, E)
  • Influenza
  • Measles, Mumps & Rubella (MMR)
  • COVID-19
  • Human Papillomavirus (HPV)
  • Respiratory Syncytial Virus (RSV)
  • Other Disease Types
• By Age Group
  • Pediatrics (0-18 yrs)
  • Adolescents (12-18 yrs)
  • Adults (19-59 yrs)
  • Geriatrics (?60 yrs)
• By End-User
  • Government Immunization Programs
  • Hospitals & Specialty Clinics
  • Retail & Community Pharmacies
  • Online / Tele-pharmacy Channels
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America commanded 39.13% of preventive vaccines market share in 2025, sustained by high per-capita spending and rapid approval frameworks such as the FDA’s Project NextGen, which cut variant clearance timelines to 6 months. Medicare’s removal of cost-sharing expanded the senior addressable pool by 12 million individuals, and Canada synchronized RSV guidance in 2025, creating a unified continental demand curve.

Asia-Pacific is forecast to post a 7.51% CAGR to 2031, the swiftest worldwide. India’s USD 420 million pneumococcal tender split between Bharat Biotech and Serum Institute exemplifies capacity localization. China’s regulator cleared 14 new vaccines in 2025, including Sinopharm’s quadrivalent flu and CanSino’s inhaled COVID-19 booster, consistent with its Five-Year Plan innovation targets. Japan broadened HPV recommendations to boys in 2024, while Australia fast-tracked GSK’s RSV shot in 2025 to maintain synchronicity across high-income APAC nodes.

Europe relies on EMA harmonization and pooled procurement that amplify bargaining power. France and Germany mandated MMR for daycare entry in 2025, lifting demand by 1.2 million doses. Digital registries across 28 African countries cut zero-dose children 19% during 2024-2025 via mobile outreach. South American momentum centers on Brazil’s national program and PAHO tenders that trim unit costs up to 35%, while Argentina added meningococcal B for infants in 2025, opening a USD 28 million procurement lane.

List of Companies Covered in this Report:

• AstraZeneca
• Bavarian Nordic
• Bharat Biotech International Ltd.
• BioNTech
• CSL Limited (Seqirus)
• Daiichi Sankyo
• Emergent Bio Solutions
• GlaxoSmithKline
• Johnson & Johnson
• Merck
• Moderna
• Novavax
• Pfizer
• Sanofi
• Serum Institute of India
• Sinopharm Group Co. Ltd.
• Sinovac Biotech
• Takeda Pharmaceuticals
• Valneva
• Walvax Biotechnology Co. Ltd.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support